Myositis Leukopak

About Myositis Leukopak

High-Yield LeukoCore Myositis Leukopak for Autoimmune Myopathy Research

LeukoCore Myositis Leukopak is collected from IRB-consented donors clinically diagnosed with an idiopathic inflammatory myopathy through IRB-approved apheresis procedures. Each leukopak contains large quantities of peripheral blood mononuclear cells (PBMCs), supporting studies of the immune response driving muscle inflammation at scale.

Why a Leukopak for Myositis Research

The idiopathic inflammatory myopathies are systemic autoimmune diseases in which lymphocytes attack skeletal muscle. Muscle biopsy shows the destination of that attack, but the effector and helper populations driving it are studied in blood — and the informative populations are rare enough that a standard draw is limiting.

• Highly differentiated cytotoxic T cells — expanded, terminally differentiated CD8 T cell populations are a recognised feature of the inflammatory myopathies, particularly inclusion body myositis, and their characterisation and sorting are yield-dependent
• Type I interferon axis in dermatomyositis — a prominent interferon signature is well established in dermatomyositis and underlies interest in JAK-STAT inhibition; interrogating interferon-responsive cells requires sufficient cells for stimulation and sorting experiments
• B cells and plasmablasts produce the defining autoantibodies — the myositis-specific autoantibodies that define clinical subsets originate in B lineage cells, whose clonality and repertoire need high input for meaningful sequencing depth
• Serotype-stratified cohorts need volume — because autoantibody serotype defines clinical phenotype in myositis, subgroup analyses divide the cohort quickly, and adequate material per donor keeps subgroup studies viable
• Multi-assay designs from one donor — immunophenotyping, functional assays, sorting, and multi-omics can all be run on a single apheresis collection, removing inter-donor variability
• Cell therapy feasibility — engineered cell approaches for refractory autoimmune disease are assessed at manufacturing-relevant scale, which apheresis material makes possible

Donor Stratification Available

• Autoantibody serotype — myositis-specific and myositis-associated antibody status where measured
• Clinical subtype — dermatomyositis, polymyositis, antisynthetase syndrome, immune-mediated necrotising myopathy, or inclusion body myositis
• Disease activity and muscle enzymes — active versus quiescent disease; creatine kinase where recorded
• Extramuscular involvement — interstitial lung disease, cutaneous involvement, or arthritis where documented
• Treatment status — treatment-naive, corticosteroids, immunosuppressants, IVIG, or biologic therapy
• HLA type — HLA-A typing included; extended typing available on request
• Matched healthy controls available — demographically matched healthy donor leukopaks

Product Features

• Research Use Only (RUO) human leukopaks
• Clinically confirmed myositis donors
• High cell yield for large-scale studies
• Processed and shipped within 24 hours of collection
• Fresh or cryopreserved options available
• Cell yield and viability reported per lot
• IRB-approved and ethically sourced
• Infectious disease testing
• HLA-A typing
• Screen donors with LeukoLot™

De-identified Donor Data

• Verified myositis diagnosis from healthcare providers
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported medication history and allergies
• Relevant clinical data including myositis subtype and severity (if available)

Applications

• Cytotoxic CD8 T cell characterisation and sorting
• Type I interferon signature and JAK-STAT pathway research
• B cell, plasmablast, and B cell receptor repertoire analysis
• Deep immunophenotyping stratified by autoantibody serotype
• Cell-based assays and cytokine profiling at scale
• Multi-omics studies including single-cell and TCR repertoire sequencing
• Cell therapy feasibility studies for refractory autoimmune disease
• Therapeutic development, screening, and mechanism-of-action work

Other Myositis Specimen Types

Matched material from the same myositis donor pool is available as myositis serum, plasma, whole blood, and PBMC. Subtype-specific cohorts are available as dermatomyositis leukopak, polymyositis PBMC, and inclusion body myositis PBMC.

Compliance and Quality Assurance

• Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
• HIPAA-compliant handling of donor information
• Rigorous donor screening and documentation

Ordering & Customization

Myositis Leukopak is available fresh or cryopreserved. For pricing, or to check current availability across our full leukopak inventory, visit our human leukopak page to browse other disease-state options and live stock status. For international shipping or regulatory documentation, please contact learnmore@sanguinebio.com to confirm regional compliance and shipping availability.